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Mucous membrane and lower respiratory building related
symptoms in relation to indoor carbon dioxide concentrations
in the 100-building BASE dataset
Introduction
Building related symptoms (BRS), sometimes called
sick building syndrome (SBS) symptoms, are a set of
symptoms with unidentified etiology frequently
reported by building occupants, especially occupants
of office buildings. The individuals who suffer from
BRS report that the symptoms occur when they
spend time indoors and that the symptoms lessen
while away from the building (Levin, 1989). Under-
standing the etiology of BRS in office buildings has
been a major challenge. Evidence supporting the
hypothesis that building characteristics and related
indoor environmental quality affects symptom occur-
rence in building occupants continues to accumulate
(Mendell, 1993, Fisk, 2000; Chao et al., 2003). BRS
include symptoms of allergies, asthma, and respirat-
ory illnesses. Indoor air quality also appears to
influence absenteeism, work performance, and health
care costs (Fisk, 2000).
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Practical implications
These results suggest that provision of sufficient per-person outdoor ventilation air, could significantly decrease
prevalence of selected building related symptoms. The observed relationship between indoor minus outdoor CO2
concentrations and mucous membrane and lower respiratory symptoms suggests that air contaminants are implicated
in the etiology of building related symptoms. Levels of indoor air pollutants that are suspected to cause building
related symptoms could be reduced by increasing ventilation rates, improving ventilation effectiveness, or reducing
sources of indoor air pollutants, if known.
Abbreviated symptom phrasing is used throughout the paper. ‘‘Dry eyes’’
abbreviates ‘‘dry, itching, irritated eyes’’. ‘‘Sore throat’’ abbreviates ‘‘sore or
dry throat’’. ‘‘Nose/sinus’’ abbreviates ‘‘stuffy or runny nose, or sinus con-
gestion’’. ‘‘Sneeze’’ abbreviates ‘‘sneezing’’. ‘‘Tight chest’’ abbreviates ‘‘chest
tightness’’. ‘‘Short breath’’ abbreviates ‘‘shortness of breath’’.
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Carbon dioxide and building related symptoms (BRS)
The primary source of carbon dioxide (CO2) in office
buildings is the respiration of building occupants. At
concentrations occurring in most indoor environments,
steady state indoor carbon dioxide (CO2) concentra-
tion above that outdoors can be considered a surrogate
for concentrations of other occupant-generated pollut-
ants, particularly bioeffluents, and for ventilation rate
per occupant, but not as a causal factor in human
health responses (ASHRAE, 2001; ACGIH, 1991).
That is, higher indoor CO2 concentrations reflect a
lower per occupant ventilation rate, and lower indoor
CO2 concentrations reflect a higher per occupant
ventilation rate. CO2 concentrations in office buildings
typically range from 350 to 2500 p.p.m. (Seppänen
et al., 1999). The threshold limit value for 8-h time-
weighted-average exposures to CO2 is 5000 p.p.m.
(ACGIH, 1991), thus CO2 concentrations encountered
in the normal operation of buildings are not expected
to cause health symptoms directly. Currently, the
American Society of Heating, Refrigeration, and Air-
conditioning Engineers (ASHRAE) recommends a
minimum office building ventilation rate in offices of
10 l/s/person, corresponding to an approximate steady
state indoor CO2 concentration of 870 p.p.m. (ASH-
RAE, 2001), based on the assumptions that outdoor
CO2 is 350 p.p.m and indoor CO2 generation rate is
0.31 l/min/person.
In an extensive review of mostly cross-sectional
studies (Seppänen et al., 1999), one half of 18 studies of
BRS in office buildings reported that increased indoor
CO2 concentrations levels were associated with a
statistically significant increase in the prevalence of
one or more BRS. Symptoms that were associated with
CO2 levels included headache, fatigue, eye symptoms,
nasal symptoms, respiratory tract symptoms, and total
symptom scores. When limiting the review to mechan-
ically ventilated and air-conditioned buildings only
(i.e., excluding naturally ventilated buildings), the
proportion of studies reporting a statistically signifi-
cant association between indoor CO2 and BRS
increased to 70% (Seppänen et al., 1999, Apte et al.,
2000). A previous analysis of the 41-building 94–96
BASE dataset (cross-sectional design) found statisti-
cally significant dose–response relationships between
indoor minus outdoor CO2 levels (dCO2) and the
following symptoms: sore throat, nose/sinus, combined
mucous membrane symptoms, tight chest, and wheeze;
the adjusted odds ratios for these symptoms ranged
from 1.1 to 1.5 per 100 p.p.m. increase in dCO2 levels
(Apte et al., 2000).
In a longitudinal study using a modified version of
the BASE questionnaire, Chao et al. (2003) found that
upper respiratory symptoms (‘‘sore/dry throat’’, ‘‘sinus
congestion’’, ‘‘cough’’, ‘‘sneezing’’) were associated
with indoor CO2 levels (OR ¼ 1.49; 95% CI, 1.09–
2.03); eye irritation and non-specific symptoms (e.g.,
‘‘headache’’, ‘‘unusual tiredness’’, ‘‘tension’’, ‘‘dizzi-
ness’’) were not related to indoor CO2 levels. Not
surprisingly, the relationship between CO2 concentra-
tions and upper respiratory symptoms in this study was
no longer statistically significant after adjusting for the
number of people in the office, since people are the
main source of CO2 in office buildings.
In this paper, we focus on building-related upper
respiratory and mucous membrane (MM) symptoms
(i.e., dry eyes, sore throat, nose/sinus, and sneeze) and
lower respiratory (LResp) symptoms (i.e., tight chest,
short breath, cough, and wheeze). We examine the
relationship of the MM and LResp symptoms to
indoor building ventilation as inferred from occupant-
generated indoor CO2 concentrations, while control-
ling for potentially confounding individual-level and
environmental variables. The analyzes presented here
expand those presented in Apte et al. (2000) to the full




The data analyzed in this paper were collected in 100
randomly selected, non-complaint, large US office
buildings from 1994 to 1998 by the US Environmental
Protection Agency for the Building Assessment Survey
and Evaluation (BASE) study (Girman et al., 1995,
Womble et al., 1996). These buildings were all at least
partially mechanically ventilated, and all but one was
air-conditioned. BASE buildings were studied during
1-week periods either in winter or summer. Environ-
mental data were collected during the same week that
the questionnaire was administered. The BASE proto-
col has been discussed fully elsewhere (Womble et al.,
1993; BASE Website).
The BASE questionnaire confidentially collected
occupant information, including sex, age, smoking
status, job characteristics, perceptions about the indoor
environment, and health and well-being. The question-
naire inquired about occurrence of the following
symptoms: dry eyes, nose/sinus, sore throat, sneeze,
tight chest, short breath, cough, wheeze, fatigue,
headache, eyestrain, back pain, nausea, hand pain,
dizziness, depression, difficulty concentrating, and dry
or itchy skin. In this study, we restrict our analyses to
the mucous membrane (dry eyes, nose/sinus, sore
throat, and sneeze) and lower respiratory (tight chest,
short breath, cough, and wheeze) symptoms. A symp-
tom was considered ‘‘building related’’ if the occupant
reported that the symptom occurred at least 1–3 days
per week during the previous month and that the
symptom improved when the occupant was away
from the building. Symptoms were analyzed both
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individually and in the following combined categories:
Mucous Membrane (MM) ¼ at least one of dry eyes,
nose/sinus, sneeze, or sore throat; Lower Respiratory
(LResp) ¼ at least one of tight chest, short breath,
cough, or wheeze.
In addition, BASE questionnaire responses were
used to test the hypothesis that subpopulations with
certain environmentally mediated health conditions are
more likely to experience and/or report BRS. The
variables used for this purpose include previously
diagnosed dust allergy, mold allergy, hayfever, eczema,
asthma, and migraine. Self-reported sensitivity to
(environmental) tobacco smoke and chemical sensitiv-
ity also were considered. The health condition variables
were included individually in some models and were
combined in other models (i.e., the health conditions
variables were combined into a general ‘‘susceptibility’’
variable for some models). It is thought that individ-
uals with these conditions may have a lower threshold
in terms of responding to factors that are associated
with the symptoms of interest.
At each BASE office building, CO2, temperature,
relative humidity, and volatile organic compounds
(VOCs) were measured at three indoor locations and
outdoors. CO2 and indoor temperature were collected
as 5-min averages. VOC samples using both canister
and multisorbent tube collection methods were collec-
ted and analyzed by gas chromatograph-mass spectr-
ometry for up to 73 VOC species. Spatial-average
pollutant concentrations and average temperatures
were calculated based on data from the three meas-
urement sites. One-day average concentrations of
dCO2, 19 VOCs, formaldehyde, carbon monoxide,
temperature, and relative humidity were calculated for
all 100 buildings.
Time-averaged workday (defined as 08.00–17.00)
difference between indoor and outdoor CO2 concen-
trations (dCO2) was calculated and served as a surro-
gate measure of ventilation rate per occupant for each
building. Only Wednesday measurements were used
since that day had a complete set of measurements.
dCO2 was calculated as follows:
dCO2 ¼ CO2indoor  CO2outdoor ð1Þ
where, CO2indoor ¼ the time-averaged indoor workday
CO2 concentration, and CO2outdoor ¼ the time average
outdoor workday CO2 concentration.
A thermal exposure (THEMEXP) variable (C-
hours) was calculated as the integrated difference
between 5-minute-average-temperature and 20C, dur-
ation-normalized in to 8.5 h of exposure. The indoor
workday-average relative humidity (RH) was calcula-
ted. Climatic and season variables were entered into a
subset of enhanced models, including heating degree-
days for the building site (HDD,C-days), cooling
degree-days for the building site (CDD,C-days), and
the season (summer or winter) during which the
building was studied.
One VOC, 1,2,4 trimethylbenzene (1,2,4-TMB), was
selected as a covariate in the regression models to
adjust for the potential affects of ambient automotive
sources on BRS. Previous analyzes have shown 1,2,4-
TMB to have statistically significant associations with
a number of MM and LResp symptoms (Apte and
Daisey, 1999). 1,2,4-TMB is found in infiltrating
outdoor air and originates from automotive sources.
Other sources of 1,2,4-TMB in office buildings may
include carpet, undercarpet, and building materials
(Apte and Daisey, 1999).
Statistical methods
Prevalence odds ratios (OR) and Wald Maximum
Likelihood (WML) statistics were calculated using
multivariate logistic regression procedures in SAS
Release 8.2 (SAS, 1989). Crude and adjusted multi-
variate models were constructed using continuous
dCO2 as the independent variable and each of the
BRS variables as dependent variables. Covariates
used in all of the multivariate models to control for
potential confounding were age, sex, presence of
carpet in workspace, smoking status, THEMEXP,
RH, and 1,2,4-TMB concentration. Heating degree-
days (HDD), cooling degree-days (CDD), and season
variables were added in enhanced models to account
for variability possibly caused by climate during the
study. Additional details regarding model building
with the BASE dataset can be found in Apte et al.
(2000).
To evaluate the ‘‘dose–response’’ relationship be-
tween the CO2 metric (dCO2) and BRS, additional
analyzes were conducted where dCO2 was divided into
five exposure categories. The dCO2 categories reflect
the 10th and 90th percentiles of the dCO2 distribution
across all 100 buildings and three bins evenly split
between these percentiles. To evaluate the dose–
response trends in the associations between dCO2
levels and BRS, an analysis of covariance approach
was used (Selvin, 1995). Dummy variables representing
the four highest dCO2 bins were constructed and used
in regression models in place of the continuous dCO2
variable. The bottom 10th percentile category served as
the referent. This approach also was used in the
previous analysis of the 94–96 BASE dataset (Apte
et al., 2000).
Additional logistic regression models used a single
categorical dCO2 variable with five interval levels as
defined above. These levels were coded using the bin-
mean dCO2 for each dCO2 level. The WML statistic
and associated P-value for this categorical variable was
used as a measure-of-fit of the dose–response relation-
ship for the adjusted associations between categorical
dCO2 measures and BRS.
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To estimate the proportion of BRS prevalence that
potentially could be avoided through improved build-
ing ventilation or elimination of indoor air pollutants,
the percent risk reduction (PRD) was calculated for
symptoms with statistically significant odds ratios. The
PRD statistic was described by Apte et al. (2000) and is
an adaptation of the attributable risk percent statistic
for situations where the rare disease assumption does
not apply. A simple formula used to calculate attrib-
utable risk percent (AR%) is
AR% ¼ ½ðRR 1Þ=RR  100 ð2Þ
where RR is the relative risk estimate for the effect of
interest (e.g., dCO2 and BRS). RR may be a risk ratio
or rate ratio (Miettinen, 1974; Jekel et al., 2001).
Alternatively, an odds ratio, which is an approxima-
tion of the risk ratio, may be used if the disease or
health outcome of interest is rare (Cole and MacMa-
hon, 1971, Jekel et al., 2001). To obtain the PRD for
symptom prevalences between 5% and 10% and an
odds ratio less than 10, Apte et al. (2000) recommen-
ded that a correction of less than )10% be applied to
the simple AR% calculation. For a symptom preval-
ence of 30% and an odds ratio less than 10, the
recommended correction is less than )20%. The
application of these corrections gives an approximate
PRD in these situations. For these analyzes, the PRD
is interpreted as the percent reduction of individuals
reporting BRS that would be expected if a given dCO2
level were reduced to the dCO2 level in the referent
group (i.e., the lowest dCO2 concentration observed
among the BASE buildings, 40 p.p.m). This interpret-
ation assumes that dCO2 concentrations represent
concentrations of causal agents.
Results
Comparison of results from the 94–96 and 94–98 BASE datasets
Table 1 provides summary statistics for environmental
covariates, individual-level covariates, and BRS
dependent variables for the participants in the full
100 building 94–98 BASE survey. Prior to development
of new models, the results of the analysis of dCO2
association with BRS in the 94–96 dataset were
compared to those in the full 100 building 94–98
dataset. This initial comparison did not include
climatic/season or the environmentally mediated health
condition variables. Table 2 compares the earlier 94–96
dataset with the full 94–98 dataset using multivariate
logistic regression models that were unadjusted and
then adjusted for SEX, AGE, CARPET, SMOKER,
THERMEXP, RH, and 1,2,4-TMB. These same cova-
riates were used in previously published analyses using
the smaller 94–96 dataset (Apte et al., 2000). The dCO2
odds ratios (ORs) are reported in units per 100 p.p.m.
The larger 94–98 BASE dataset analysis yielded similar
but weaker findings compared with the smaller 94–96
dataset, with smaller adjusted ORs ranging from 1.15
to 1.21 per 100 p.p.m. increase in dCO2 for sore throat
and wheeze. The effect for dry eyes, nose/sinus, and
MM observed in the 94–96 dataset was not apparent in
the 94–98 dataset. As stated above, this paper focuses
on MM and LResp symptoms. However, for com-
pleteness we report that none of the associations of
dCO2 with other symptoms reported in the BASE
dataset were statistically significant. This finding is
consistent with those reported in Apte et al. (2000) for
the 94–96 BASE dataset.
Enhanced modeling
Differences in climate may affect regional variability in
building codes, design, construction, and operation
and, thus, could influence the environmental condi-
tions inside office buildings. In an attempt to account
Table 1 Summary statistics for environmental covariates, individual-level covariates, and
BRS dependent variables in the 100 building 94–98 BASE Study dataset
Variable n Percent Mean SD Min Max
Environmental covariates
dCO2 (p.p.m./100) 100 2.6 1.3 0.40 6.1
THERMEXP (C-hours w/T > 20C) 100 25* 6.8 2.2 43
1,2,4-TMB (p.p.b) 100 0.98 1.1 0.05 6.7
Smoking building 100 25%
Winter season 100 49%
Average RH < 20% 100 16%
Heating degree-days (C-days) 100 2200 1163 114 4616
Cooling degree-days (C-days) 100 801 583 22 2243
Individual-level covariates
Current smoker 4304 15%
Carpet in workspace 4292 89%
Female 4295 66%
Age ‡ 40 years 4294 55%
Dust allergy (diagnosed) 4158 32%
Mold allergy (diagnosed) 4093 25%
Hay fever (diagnosed) 4073 29%
Combined allergy 4208 42%
Migraine (diagnosed) 4099 21%
Asthma (diagnosed) 4032 12%
Eczema 3972 9%
Sensitivity to tobacco smoke 4263 56%
Sensitivity to chemicals in the air 4276 49%
Sensitivity to tobacco or chemicals 4311 67%





dry eyes 4245 19%




tight chest 4302 2%
short breath 4287 2%
cough 4260 5%
wheeze 4301 2%
*The geometric mean 1,2,4-TMB concentration across the 100 BASE buildings was
0.6 p.p.b and the geometric standard deviation was 2.5.
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for the variance due to climatic differences, SEASON,
heating degree-days (HDD), and cooling degree-days
(CDD) variables were added to further refine the initial
models. For simplicity of presentation, Table 3 lists the
basic set of variables used in all the models described
below. Additionally, variables representing the follow-
ing selected environmentally mediated health condi-
tions, or ‘‘susceptibilities’’, were added into these
enhance models: dust allergy, mold allergy, hayfever,
eczema, asthma, migraine, sensitivity to (environmen-
tal) tobacco smoke, and chemical sensitivity. All of the
health condition variables showed some statistically
significant relationships with symptoms, thus support-
ing the hypothesis that individuals with these condi-
tions are more susceptible to experiencing BRS than
those without these conditions. In particular, diag-
nosed asthma and self-reported chemical sensitivity
were consistent predictors of lower respiratory and all
symptoms, respectively. Statistically significant ORs
for BRS ranged from 1.52 (95% CI, 1.14–2.01) to 11.13
(95% CI, 2.72–45.53) comparing individuals with one
or more susceptibility with those without any suscep-
tibility.
After including the health condition variables, the
dCO2 variable was no longer statistically significant
with the exception of sore throat (data not shown). An
inspection of the model output suggested that this
might be due to reduced statistical power; many
observations had missing values for the health condi-
tion variables, reducing the sample size to about 3700
observations. To create a more parsimonious model, a
new variable was defined such that any individual who
reported having one or more of the environmentally
mediated health conditions was considered to be
‘‘susceptible’’ (SUSCEPT). The increase in sample size
achieved by combining the health condition variables
resulted in fewer observations being dropped due to
missing values, yielding a sample size of about 4200. In
these models, adjusted odds ratios per 100 p.p.m.
increases in dCO2 were statistically significant for
MM (OR ¼ 1.08; 95% CI, 1.02–1.15), dry eyes
(OR ¼ 1.09; 95% CI, 1.02–1.17), sore throat (OR ¼
1.21; 95% CI, 1.09–1.34), nose/sinus (OR ¼ 1.11; 95%
CI, 1.02–1.20), sneeze (OR ¼ 1.09; 95% CI, 1.00–
1.19), and wheeze (OR ¼ 1.23; 95% CI, 1.01–1.48)
symptoms (Table 4). Table 4 provides a comparison
between the crude and adjusted models and also
provides the ORs and 95% confidence intervals for
the FEMALE and SUSCEPT variables. Other statis-
tically significant covariates in these models were AGE
(OR range: 1.2–1.4), SMOKER (OR range: 1.4–2.2),
RH (OR range: 1.6–2.0), 1,2,4-TMB (OR ¼ 1.3 for
short breath), and CDD (OR range: 0.96–0.98 per
100C-days).
CO2 dose–response
Figure 1 presents the results of the analysis of the trend
between increasing dCO2 levels and reported symp-
toms after adjustment for all of the covariates listed in
Table 3 plus SUSCEPT. The data from buildings in the




dCO2 OR (per 100 p.p.m)
94–98 BASE Dataset
dCO2 OR (per 100 p.p.m)
Crude Adjusted Crude Adjusted
MM 1.10 (1.03–1.18)‡ 1.11 (1.02–1.20) 1.04 (0.99–1.09) 1.05 (0.98–1.11)
Dry eyes 1.11 (1.03–1.20) 1.13 (1.03–1.24) 1.06 (1.00–1.12) 1.06 (1.00–1.12)
Sore throat 1.30 (1.16–1.47)‡ 1.39 (1.19–1.62)‡ 1.14 (1.05–1.25)‡ 1.15 (1.05–1.26)‡
Nose/sinus 1.11 (1.02–1.22) 1.15 (1.03–1.28) 1.05 (0.98–1.12) 1.05 (0.98–1.13)
Sneeze 1.03 (0.94–1.14) 1.03 (0.92–1.16) 1.04 (0.97–1.11) 1.04 (0.97–1.12)
LResp 1.10 (0.98–1.22) 1.10 (0.97–1.26) 1.03 (0.95–1.12) 1.03 (0.94–1.12)
Tight chest 1.11 (0.90–1.37) 1.27 (0.99–1.65) 1.03 (0.89–1.20) 1.09 (0.93–1.28)
Short breath 1.08 (0.87–1.34) 1.18 (0.90–1.56) 1.05 (0.89–1.24) 1.09 (0.91–1.29)
Cough 1.04 (0.90–1.19) 1.02 (0.86–1.20) 0.97 (0.88–1.08) 0.96 (0.86–1.07)
Wheeze 1.37 (1.12–1.68)‡ 1.42 (1.09–1.85) 1.22 (1.04–1.42) 1.21 (1.03–1.43)
*Adjusted for age, sex, presence of carpet in workspace, smoking status, THERMEXP, RH, and 1,2,4-TMB. These models did not include environmentally mediated health condition
variables (e.g., asthma, allergies, chemical sensitivity, etc.).
Values in parentheses are the 95% confidence interval (CI). ORs and CIs given in bold are statistically significant at the 95% confidence level or higher.
P £ 0.005.
Table 3 Descriptions of covariates included in all enhanced models
Variable Description
SEX 0: male; 1: female
AGE 0: age < 40 years; 1: age ‡ 40 years
CARPET 0: no carpet at workstation; 1: carpet on most or all of floor at
workstation
SMOKER 0: never or former smoker; 1: current smoker
THERMEXP 8.5 h workday normalized degree Celsius hours above 20C
RH 0: mean RH < 20%; 1: mean RH ‡ 20%
1,2,4-TMB indoor canister 1,2,4-Trimethylbenzene; automobile exhaust marker
SEASON 0: summer; 1: winter
CDD Cooling degree-days (C-days)
HDD Heating degree-days (C-days)
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lowest dCO2 bin served as the referent. Total sample
size for each symptom also is shown (n range: 4108–
4225). Visually, the plots suggest possible dose–
response relationships, but usually with the odds ratio
in one exposure category deviating from the expected
dose–response pattern. Based on the WML tests for
statistically significant trends, the following symptoms
or symptom groups were found to have a statistically
significant dose–response relationship with dCO2
(P < 0.05): MM, dry eyes, sore throat (P < 0.005),
nose/sinus, sneeze, and wheeze.
Potential for BRS risk reduction
Using the percent risk reduction (PRD) statistic (Apte
et al., 2000), we estimated the maximum potential
reduction in BRS that could be achieved if dCO2 were
reduced from 608 p.p.m. (the highest dCO2 concentra-
tion among the BASE buildings) to 40 p.p.m. (the
lowest dCO2 concentration among the BASE build-
ings). Based on the adjusted regression models reported
in Table 4, the calculated ORs corresponding to a
dCO2 concentration of 608 p.p.m. for dry eyes, sore
throat, nose/sinus, sneeze, and wheeze are 6.19, 6.87,
6.30, 6.19, and 6.99, respectively. In BASE buildings
with the highest dCO2 concentrations, the implied
potential maximum reduction in prevalence of these
symptoms is roughly 64%, 75%, 64%, 74%, and 85%,
respectively. As discussed above and in Apte et al.
(2000), a correction can be applied when the prevalence
of the outcome of interest is 5% or greater to give a
more conservative estimate. Since the prevalence of
wheeze was less than 5%, no correction was applied.
Prevalences for dry eyes, sore throat, nose/sinus, and
sneeze were higher (see Table 1), thus, corrections of




It should be re-emphasized here that there is no direct
causal link between exposure to CO2 and BRS, but
rather dCO2 is a surrogate measure of ventilation rate
per occupant and is approximately correlated with
other indoor pollutants that may cause BRS. The
results of these analyses suggest that there is an
association between elevated dCO2 levels and increased
prevalence of certain mucous membrane and lower
respiratory building related symptoms in the 100
building 94–98 BASE dataset. These findings were
evident in crude regression models and persisted
through adjustment for a number of potential con-
founders.
Analysis of trend indicates that in the fully adjusted
model (i.e., the model that include dCO2, the covariates
listed in Table 3, and SUSCEPT), a statistically signi-
ficant dose–response trend is apparent for the relation-
ship between dCO2 and MM, dry eyes, sore throat,
nose/sinus, sneeze, and wheeze symptoms in the 94–98,
100 building BASE dataset. This is consistent with the
findings for the 94–96 BASE dataset as discussed in
Apte et al. (2000); however, the 95% confidence
intervals around the odds ratio point estimates are
considerably tighter using the 94–98 BASE dataset as
would be expected given the larger sample size.
The odds ratios for the associations of symptoms
with the highest average observed difference between
indoor and outdoor CO2 concentrations may indicate





dCO2 OR (per 100 p.p.m.) Individual risk factors
Crude Adjusted FEMALE§ SUSCEPT–
MM 1.04 (0.99–1.09) 1.08 (1.02–1.15) 2.07 (1.78–2.42)‡ 1.88 (1.55–2.29)‡
Dry eyes 1.06 (1.00–1.12) 1.09 (1.02–1.17) 2.18 (1.80–2.63)‡ 2.14 (1.66–2.74)‡
Sore throat 1.14 (1.05–1.25)‡ 1.21 (1.09–1.34)‡ 2.12 (1.56–2.89)‡ 2.21 (1.46–3.35)‡
Nose/sinus 1.05 (0.98–1.12) 1.11 (1.02–1.20) 1.80 (1.45–2.24)‡ 2.34 (1.73–3.16)‡
Sneeze 1.04 (0.97–1.11) 1.09 (1.00–1.19) 1.99 (1.58–2.52) 1.52 (1.14–2.01)
LResp 1.03 (0.95–1.12) 1.08 (0.97–1.19) 1.75 (1.34–2.29)‡ 2.69 (1.81–4.01)‡
Tight chest 1.03 (0.89–1.20) 1.07 (0.90–1.28) 1.84 (1.10–3.07) 11.13 (2.72–45.53)‡
Short breath 1.05 (0.89–1.24) 1.07 (0.87–1.32) 3.00 (1.53–5.89)‡ 5.53 (1.72–17.80)‡
Cough 0.98 (0.88–1.08) 1.03 (0.91–1.16) 1.80 (1.29–2.51)‡ 1.90 (1.22–2.95)‡
Wheeze 1.22 (1.04–1.42) 1.23 (1.01–1.48) 1.69 (0.97–2.92) 2.44 (1.10–5.40)
*Values in parentheses are the 95% confidence interval (CI). ORs and CIs given in bold are statistically significant at the 95% confidence level or higher.
Adjusted for covariates listed in Table 3 and the susceptible population variable SUSCEPT.
P £ 0.005.
§Adjusted odds ratio for females vs. males of having the BRS symptoms.
–One or more of the following susceptibilities: dust allergy, mold allergy, hay fever, eczema, asthma, migraine, sensitivity to (environmental) tobacco smoke, chemical sensitivity.
Erdmann and Apte
132
the maximum potential to reduce selected symptoms in
BASE office buildings, which are thought to be
representative of typical US office buildings. Based
on the assumption that dCO2 concentrations are
correlated with concentrations of BRS causal agents,
the implied potential maximum reductions in BRS
prevalence that could be achieved by reducing dCO2
concentrations in the BASE buildings are on average
roughly 64%, 75%, 64%, 74%, and 85% for dry eyes,
sore throat, nose/sinus, sneeze, and wheeze, respect-
ively. The reader should be aware that these reductions
are based on logistic regression models using the entire
BASE building dataset, not just the extreme cases.
However it may be impractical in most cases to supply
sufficient ventilation to buildings to achieve the greatest
reduction in prevalence of these symptoms. Practical
approaches to achieve reductions in dCO2 and corre-
lated indoor air pollutants could come through increa-
ses in ventilation rates, improved effectiveness in
providing fresh air to the occupants breathing zone,
or through identification of the symptom-causing
agents in the indoor air and control of their sources.
In no case in this study were the indoor average or the
peak indoor CO2 concentrations extraordinarily high;
only two buildings had peak indoor (absolute) CO2
concentrations routinely above 1000 p.p.m.
Susceptible population
The subpopulation of the office buildings with envi-
ronmentally mediated health conditions appears to
play a strong role in driving the prevalence of BRS.
The SUSCEPT variable was a consistently strong and
statistically significant predictor of symptoms in the
full 94–98 BASE dataset. The lowest adjusted odds
ratios observed in this study of BRS risk for individuals
with any of the environmental susceptibilities (i.e.,
allergies, asthma, migraine, eczema, hayfever, chemical
and/or tobacco sensitivity) were around 1.9. The odds
of a susceptible individual having short breath in their
office building were 5.5 times greater than those of a
nonsensitive individual – the odds were 11.1 times
greater for tight chest. Interestingly, the prevalence of
SUSCEPT in the BASE study building population is
very high (81%), although the prevalences of the lower
respiratory symptoms were on the order of a few
percent.
Epidemiological considerations
Epidemiological considerations regarding these ana-
lyses were discussed in detail in Apte et al. (2000). We
refer the reader to that paper for a discussion of bias
and confounding, biological plausibility, and consis-
tency of findings in BASE study analyses. One statis-
tical concern is the potential impact of cross-level bias.
This issue has not been addressed in the analyses
presented here. The concern relates to the fact that the
individual level observations within a building are not
truly independent as the environments of the occupants
are shared. The extent to which this bias might lead to
error in the estimates of the true relationships is
thought to be small, but more sophisticated methods
would be needed to verify the assumption.
Conclusion
The BASE dataset is a valuable source of information
about the US building stock, providing an opportunity
for identification of causal factors of building related
symptoms and for developing solutions to lower
their prevalence in buildings. After adjusting for
selected covariates, we found statistically significant
Fig. 1 Dose–response relationship between binned dCO2 and
MM and LResp symptoms in 100 building 94–98 BASE dataset.
Odds ratios and 95% confidence intervals are the results of
adjusted models that included covariates listed in Table 3 and
the SUSCEPT variable. dCO2 bins reflect the 10th and 90th
percentiles of the dCO2 distribution across all 100 buildings and
three bins evenly split between them. The P-values reflect the fit
of the dose–response model with smaller P-values indicating a
better fit
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associations of mucous membrane (MM) and lower
respiratory (LResp) building related symptoms (BRS)
with increasing dCO2. Covariate-adjusted odds ratios
per 100 p.p.m. increases in dCO2 were statistically
significant for dry eyes, sore throat, nose/sinus, sneeze,
and wheeze symptoms and ranged from 1.1 to 1.2. The
data indicate that in the most highly ventilated
buildings (lowest dCO2) these symptoms may be
reduced by a maximum of 64–85% depending upon
the symptom, compared to buildings that just meet the
ASHRAE minimum ventilation standard. These re-
sults suggest that reducing indoor CO2 levels to
approximately outdoor levels through increases in the
ventilation rates per person among typical office
buildings will reduce the prevalence of several symp-
toms, even when these buildings meet the existing
ASHRAE ventilation standard for office buildings. The
magnitude of the reduction depends on the magnitude
of the increase in ventilation rates, improvement in
ventilation effectiveness, and whether sources of BRS-
causing agents are eliminated or reduced.
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